- Home
- A-Z Publications
- Current Drug Targets
- Previous Issues
- Volume 18, Issue 10, 2017
Current Drug Targets - Volume 18, Issue 10, 2017
Volume 18, Issue 10, 2017
-
-
Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Authors: Maria Strazzullo and Maria Rosaria MatarazzoMammalian reproduction is a complex phenomenon. Human fertility is highly impacted from environmental exposure to toxicants as well as nutrients. The burden of environmental stimuli is heavy and multifaceted. The contaminant sources are many, often occult, and at present, the wide range of positive and negative consequences on the ecosystem and the human health is only partially understood. Compounds der Read More
-
-
-
The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Authors: Wenwen Zhang, Zhaojun Shen, Hui Luo, Xiaoli Hu, Lihong Zheng and Xueqiong ZhuBackground: Ovarian cancer is the leading cause of deaths attributable to gynecologic malignancies. Late diagnosis and a high tendency of metastasis and drug resistance often lead to recurrence and poor outcomes. Anti-angiogenesis is considered a promising therapeutic strategy for recurrent ovarian cancers. Anti-VEGF body, bevacizumab, is an angiogenesis inhibitor with demonstrated activity and tolerable toxicity. Read More
-
-
-
Reproductive Toxicity of T Cells in Early Life: Abnormal Immune Development and Postnatal Diseases
Authors: Han-xiao Liu, Aifang Jiang, Ting Chen, Wen Qu, Hui-yi Yan and Jie PingImmunity is a balanced status with adequate biological defenses to recognize and fight “non-self”, as well as adequate tolerance to recognize “self”. To maintain this immune homeostasis, a well-organized T cell immune network is required, which in part depends on the well-controlled development of alternative effector T cells, with different cytokine repertoires. Recent researches have pointed that developing fetal T c Read More
-
-
-
CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Authors: Chengming Sun, Ping Duan and Caifu LuanBackground: The CCAAT/enhancer binding proteins (C/EBPs) form a family of transcription factors regulating many genes’ expression in a variety of cells/tissues/organs at different developmental stages. With their capability of binding to their cognate DNA elements and through protein-protein interactions, C/EBPs modulate diverse functions including cell differentiation, metabolism, and immune response, under both physiologic Read More
-
-
-
Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Authors: Shi-wen Jiang, Siliang Xu, Haibin Chen, Jiayin Liu and Ping DuanSET (SE translocation, SET) is an evolutionarily conserved gene broadly expressed in various human tissues, especially in the gonadal and neural system. As a multitasking protein, SET is involved in essential cell processes such as histone modification, chromatin remodeling, DNA repair, gene transcription, and androgen synthesis. Recent studies showed that SET is overexpressed in breast cancers, ovary cancers and a variety Read More
-
-
-
Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Authors: Jinping Li, Haibin Chen, John R.Curcuru, Sheena Patel, Taylor O. Johns, Dimple Patel, Hua Qian and Shi-wen JiangBackground: HE4 may be a valuable early indicator of the recurrence of gynecologic cancers. Numerous studies have shown that high expression levels of serum HE4 correlate with ovarian and endometrial cancer recurrence. High HE4 levels may be an independent factor to predict these cancers’ poor prognosis. Objective: This literature review investigates the relationship between serum HE4 levels and the recurrence of Read More
-
-
-
Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Authors: Xuejing Song, Xiucui Luo, Quansheng Gao, Yuhuan Wang, Qing Gao and Wei LongBackground: Preeclampsia, a gestational disease characterized by hypertension and proteinuria twenty weeks into pregnancy, is one of the leading causes of fetal and maternal mortality. Although multiple genetic and environmental factors are found to be related to the preeclampsia risk, the pathogenic pathways remain largely undefined. The placenta plays a critical role in the fetal development by carrying out the barrier, fe Read More
-
-
-
Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Authors: Ping Duan, Lili Fan, Quansheng Gao, Bal Mukunda Silwal, Mulan Ren, Yang Shen and Wanglei QuSpecific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The additi Read More
-
-
-
Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer’s Disease
Authors: Patrizia Russo, Aliaksei Kisialiou, Rossana Moroni, Giulia Prinzi and Massimo FiniBackground: Cholinergic transmission loss is one of the major features in Alzheimer's Disease (AD). Acetylcholinesterase inhibitors (AChEI) are moderately active in AD. α7nAChR (alpha-7 nicotinic acetylcholine receptor), encoded by CHRNA7 (Nicotinic Cholinergic Receptor Alpha-7 gene), is involved in the cholinergic neurotransmission and AD pathogenesis. α7nAChR is a putative receptor of amyloid beta (Aβ). The complex α Read More
-
-
-
Recent Advancement and Technological Aspects of Pulsatile Drug Delivery System - A Laconic Review
Authors: Vinay Pandit, Ajay Kumar, Mahendra S. Ashawat, Chander P. Verma and Pravin KumarBackground: Pulsatile drug delivery system (PDDS) shows potential significance in the field of drug delivery to release the maximum amount of drug at a definite site and at specific time. PDDS are mainly time controlled delivery devices having a definite pause period for drug release, which is not affected by acidity, alkalinity, motility and enzymes present in the gastrointestinal tract. Pulsatile medication possess the potential Read More
-
-
-
Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review
Authors: Simone A.M. Badal, William D. Aiken and Sheray N. ChinBackground: Renal cell carcinoma (RCC) accounts for 2% of all adult malignancies and is associated with a case fatality rate as high as 40%. RCC has been on the rise for the last 6 decades at a steady increase of 2% per annum. Much work has been done to uncover the pathogenesis of the disease and the role of angiogenesis has been a recurrent denominator connected to vascular endothelial growth factor (VEGF) and its Read More
-
-
-
Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Authors: Tiruveedi Vijaya Lakshmi, Swarna Bale, Amit Khurana and Chandraiah GoduguTankyrases belong to a group of enzymes called poly ADP ribosyl polymerases (PARPs). With the advent of a new class of small molecule inhibitors of PARP for clinical use like OLAPARIB; that gained accelerated approval by the USFDA in treating ovarian and breast cancers, the horizons of the PARPs as a novel target in various disease conditions has risen. Tankyrases (PARP 5) are yet another class of PARPs that perform poly AD Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cdt
Journal
10
5
false
en
